Are you Dr. Munn?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 42 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1120 15th St
Augusta, GA 30912Phone+1 706-721-3626Fax+1 706-721-2643- Is this information wrong?
Summary
- Dr. David Munn, MD is a pediatric hematologist/oncologist in Augusta, Georgia. He is currently licensed to practice medicine in Georgia. He is a Professor at Medical College of Georgia at Georgia Health Sciences University.
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1987 - 1990
- Case Western Reserve Univ/Univ Hosps Cleveland Med Ctr/Rainbow Babies and Childrens HospitalResidency, Pediatrics, 1984 - 1987
- Medical College of Georgia at Augusta UniversityClass of 1984
Certifications & Licensure
- GA State Medical License 1990 - 2015
Publications & Presentations
PubMed
- 196 citationsSTING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO ActivationHenrique Lemos, Eslam Mohamed, Lei Huang, Rong Ou, Gabriela Pacholczyk
Cancer Research. 2016-04-15 - 628 citationsPlasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenaseMadhav D. Sharma, Babak Baban, Phillip Chandler, De Yan Hou, Nagendra Singh
The Journal of Clinical Investigation. 2007-09-04 - 669 citationsIDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and ToleranceDavid H. Munn, Andrew L. Mellor
Trends in Immunology. 2016-03-01
Press Mentions
- Novel Immunotherapy Beneficial to Children with Relapsed Brain Tumours: ResearchApril 25th, 2023
- Novel Treatment Regimen Appears Well Tolerated, Beneficial to Children with Relapsed Brain TumorsApril 25th, 2023
- Loss of Indoleamine-2,3-Dioxygenase-1 (IDO1) in Knockout Mice Does Not Affect the Development of Skin Lesions in the Imiquimod-Induced Mouse Model of PsoriasisFebruary 28th, 2022
- Join now to see all
Grant Support
- Ido-Mediated Immune Regulation In Established TumorsNational Cancer Institute2010–2012
- Role Of IDO MalignancyNational Cancer Institute2010–2011
- Ido-Expressing Immunoregulatory Dendritic CellsNational Cancer Institute2010–2011
- Role Of IDO MalignancyNational Cancer Institute2007–2009
- Ido-Expressing Plasmacytoid Dendritic Cells And TumorsNational Cancer Institute2005–2009
- Ido-Expressing Immunoregulatory Dendritic CellsNational Cancer Institute2003–2009
- Role Of IDO In MalignancyNational Cancer Institute2003–2006
- Macrophage Mediated Immunoregulation VIA TryptophanNational Heart, Lung, And Blood Institute1999–2002
- Inhibition Of T Cells By Tryptophan DegradationNational Institute Of Allergy And Infectious Diseases1998–1999
- Regulation Of Macrophage ApoptosisNational Heart, Lung, And Blood Institute1995–1997